The bill proposes the enactment of section 3902.65 of the Revised Code, which aims to cap cost-sharing for prescription insulin drugs, diabetes devices, and diabetic ketoacidosis devices. It defines key terms such as "prescription insulin drug," "diabetes device," and "diabetic ketoacidosis device," establishing a framework for what constitutes these items. The bill stipulates that health plan issuers cannot require cost-sharing that exceeds $35 for a thirty-day supply of all covered prescription insulin drugs and $100 for a thirty-day supply of all covered diabetes devices or diabetic ketoacidosis devices.

Additionally, the bill clarifies that these cost-sharing limitations apply regardless of any other cost-sharing requirements that may typically apply under a health benefit plan, such as deductibles or copayments. It also allows health plan issuers the flexibility to reduce a covered person's cost-sharing requirement to amounts lower than those specified in the bill. This legislation is designed to make essential diabetes-related medications and devices more affordable for individuals who require them.